Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeResources
Your patients are more open
to respiratory vaccines
than you may think1The good news is that 8 out of 10 patients* 
would accept your recommendation.2Flu • COVID-19 • Pneumococcal Pneumonia • RSV

*Among patients aged 65+ in a Pfizer US survey (n=1482), September-October 2025.

RSV=respiratory syncytial virus.

Actor portrayals.

Your patients are more open
to respiratory vaccines
than you may think1The good news is that 8 out of 10 patients*
would accept your recommendation.2Flu • COVID-19 • Pneumococcal Pneumonia • RSV

*Among patients aged 65+ in a Pfizer US survey (n=1482), September-October 2025. 

RSV=respiratory syncytial virus.

Actor portrayals.

 Your patients are more open to respiratory vaccines than you may think1Your patients are more open to respiratory vaccines 
than you may think1The good news is that 8 out of 10 patients* would accept your recommendation.2

*Among patients aged 65+ in a Pfizer US survey (n=1482), September-October 2025.

The risk is real, and the impact can be severe3The risk is real, and the impact can be severe3Respiratory infections remain one of the most consistent, preventable drivers of health complications among older adults and those with underlying medical conditions.4-10~1 million adults are hospitalized with vaccine-preventable respiratory infections each year, leading to outcomes that can significantly impact patients’ health and daily lives.11-17

Vaccine-preventable respiratory infections can exacerbate conditions like COPD, asthma, diabetes, and cardiovascular disease.4-10,18,19

Vaccines are recognized as one of the most effective ways to help protect individuals against certain respiratory diseases, but adult vaccination rates remain significantly below public health goals.20,21

COPD=chronic obstructive pulmonary disease.

See how recommending respiratory vaccines can make the difference for your patients.1

Your patients want to hear from youYour patients want to hear from youPatients rely on healthcare professionals to help them make confident healthcare decisions—including vaccination.

8 out of 10 patients aged 65 years and older† would accept a vaccine recommended by a healthcare professional.2

†In a Pfizer US survey (n=1482), September-October 2025.

 As a healthcare professional, you are a trusted source of health information. Your respiratory vaccine recommendations can help protect your patients.1 As a healthcare professional, you are a trusted source of health information. Your respiratory vaccine recommendations can help protect your patients.1 As a healthcare professional, you are a trusted source of health information. Your respiratory vaccine recommendations can help protect your patients.1 Your vaccine recommendation can make the differenceYour vaccine recommendation can make the differenceYour patients look to you to help manage and protect their health.Your adult patients are more likely to get vaccinated when they receive both a recommendation and a clear vaccination plan.1 Recommend and help them plan in the same visit.​

Your recommendation is the most important factor in your patients getting vaccinated against respiratory infections.1

This Vaccine Conversation Guide provides practical support, based on validated conversation frameworks, that can help you have effective vaccine conversation with your patients.

If all recommended vaccines can’t be administered during a
single visit, schedule a follow-up appointment.

Support the conversationLoading Some patients may need more than one respiratory vaccine. Depending on individual needs, that could mean getting two vaccines during the same visit or planning vaccinations over multiple appointments.21Patients who ask questions about vaccines are patients who are willing to listen1Patients who ask questions about vaccines are patients who are willing to listen1Questions don’t necessarily signal vaccine resistance. Your patients may just want to know more.  Your patients trust you.

Helping them understand their personal risk and the benefits and risks of vaccination is an important way to follow through on your recommendation.1

Frequently Asked Questions addresses common vaccine questions with patient-friendly responses that can help reinforce your vaccine recommendation.

Download the FAQLoading Each patient conversation is an opportunity to help lower the impact of respiratory illness.Give them your vaccine recommendation.
Make a plan. Help protect their health. Each patient conversation is an opportunity to help lower the impact of respiratory illness. Give them your vaccine recommendation.
Make a plan. Help protect their health. Each patient conversation is an opportunity to help lower the impact of respiratory illness. Give them your vaccine recommendation.
Make a plan. Help protect their health. ButtonLoading
Each patient conversation is an opportunity to help lower the impact of respiratory illness.
Give them your vaccine recommendation.
Make a plan. Help protect their health.
 Learn more about vaccine options from Pfizer Learn more about vaccine options from Pfizer Get additional helpful resources LoadingReferences:Adult immunization standards. Centers for Disease Control and Prevention. Published August 9, 2024. Accessed July 22, 2026. https://www.cdc.gov/vaccines-adults/hcp/imz-standards/index.html Data on File. Pfizer Inc.; 2025.Weyand CM, Goronzy JJ. Aging of the immune system. Mechanisms and therapeutic targets. Ann Am Thorac Soc. 2016;13(suppl 5):S422-S428.Pneumococcal disease: causes and how it spreads. Centers for Disease Control and Prevention. Published February 14, 2024. Accessed July 22, 2026. https://www.cdc.gov/pneumococcal/causes/index.htmlRSV vaccine guidance for adults. Centers for Disease Control and Prevention. Updated February 24, 2026. Accessed July 27, 2026. https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html Hounkpatin H, Stuart B, Zhu S, et al. Post-consultation acute respiratory tract infection recovery: a latent class-informed analysis of individual patient data. Br J Gen Pract. 2023;73(728):e196-e203.Underlying conditions and the higher risk for severe COVID-19. Centers for Disease Control and Prevention. Updated February 6, 2025. Accessed July 22, 2026. https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html Basilio P. Influenza hospitalization risk increases with each additional underlying condition. Infectious Disease Advisor. Published June 11, 2025. Accessed June 11, 2025. https://www.infectiousdiseaseadvisor.com/news/influenza-hospitalizations-increase-with-underlying-conditions/ Prasad N, Walker TA, Waite B, et al. Respiratory syncytial virus-associated hospitalizations among adults with chronic medical conditions. Clin Infect Dis. 2021;73(1):e158-e163. Grant LR, Meche A, McGrath L, et al. Risk of pneumococcal disease in US adults by age and risk profile. Open Forum Infect Dis. 2023;10(5):ofad192. Kobayashi M, Leidner AJ, Gierke R, et al. Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: recommendations of the Advisory Committee on Immunization Practices—United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(1):1-8. RESP-NET (Respiratory Virus Hospitalization Surveillance Network) Interactive Dashboard. Centers for Disease Control and Prevention. Updated June 5, 2026. Accessed June 11, 2026. https://www.cdc.gov/resp-net/dashboard/index.htmlEstimates of the total resident population and resident population age 18 years and older for the United States, regions, states, District of Columbia, and Puerto Rico: July 1, 2025 (SCPRC-EST2025-18+POP). US Census Bureau, Population Division. Released January 2026.Cong B, Dighero I, Zhang T, et al. Understanding the age spectrum of respiratory syncytial virus associated hospitalisation and mortality burden based on statistical modelling methods: a systematic analysis. BMC Med. 2023;21:224. Paget J, Staadegaard L, Wang X, et al. Global and national influenza-associated hospitalisation rates: estimates for 40 countries and administrative regions. J Glob Health. 2023;13:04003. Palmer S, Cunniffe N, Donnelly R. COVID-19 hospitalization rates rise exponentially with age, inversely proportional to thymic T-cell production. J R Soc Interface. 2021;18(176):20200982. Curran D, Cabrera ES, Bracke B, et al. Impact of respiratory syncytial virus disease on quality of life in adults aged ≥50 years: a qualitative patient experience cross-sectional study. Influenza Other Respir Viruses. 2022;16(3):462-473. Ghaswalla P, Hitchens A, Candrilli SD, et al. Prevalence of underlying conditions associated with higher risk for severe RSV, influenza, or COVID-19 in adults in the United States, 2017-2018. Open Forum Infect Dis. 2023;10(suppl 2):S492-S493. Abstract 903. Abbadi A, Gentili S, Tsoumani E, et al. Impact of lower-respiratory tract infections on healthcare utilization and mortality in older adults: a Swedish population-based cohort study. Aging Clin Exp Res. 2024;36(1):146.How to talk with our heart patients about adult vaccinations: leveraging the cardiovascular care team’s role to facilitate timely immunization. CardioSmart. American College of Cardiology. Last edited May 15, 2025. Accessed July 23, 2026. https://www.cardiosmart.org/assets/discussion-guide/how-to-talk-with-our-heart-patients-about-adult-vaccinationsMaggi S, Launay O, Dawson R. Respiratory virus vaccines: pathways to recommendations and enhanced coverage for at-risk populations. Infect Dis Ther. 2025;14(suppl 1):S99-S114.

To report an adverse event, please call 1‑800‑438‑1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-UNP-USA-9270
You are now leaving PfizerProYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.